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The stomach contents contain of both acid and proteolytic enzymes. How the stomach digests food with-
out damaging itself remained a topic of investigation for decades. One candidate was gastric urease,
which neutralized acid by producing ammonia from urea diffusing from the blood and potentially could
protect the stomach. Discovery that gastric urease was not mammalian resulted in a research hiatus until
discovery that gastric urease was produce by Helicobacter pylori which caused gastritis, peptic ulcer and
gastric cancer. Gastric urease allows the organism to colonize the acidic stomach and serves as a biomar-
ker for the presence of H. pylori. Important clinical tests for H. pylori, the rapid urease test and urea breath
test, are based on gastric urease. Rapid urease tests use gastric biopsies or mucus placed in a device con-
taining urea and an indicator of pH change, typically phenol red. Urea breath tests measure the change in
isotope enrichment of 13C- or 14CO2 in breath following oral administration of labeled urea. The urea
breath test is non-invasive, convenient and accurate and the most widely used test for non-invasive test
for detection of active H. pylori infection and for confirmation of cure after eradication therapy.
 2018 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction medical devices designed to detect breath ammonia originally pro-Ammonia was first identified in the stomach in 1852 and since
that time has remained a target of investigation [1]. Even today,duced in the stomach are in use clinically to detect infection with
the Gram negative bacterium, Helicobacter pylori, an important
human pathogen that despite a decline in prevalence still infects
approximately 50% of humans worldwide. H. pylori infection is
the most common causative agent of gastritis, peptic ulcers and
gastric cancer [2]. The presence of urease in the stomach was
discovered early in the 20th century (reviewed in [1] and [3]).
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urease including the range of animals in which urease could be
found as well as its role in health and disease.
In the late 19th century, it was discovered that gastric cancer
was somehow related to achlorhydria or loss of the stomach’s abil-
ity to make acid [4]. This observation prompted research in gastric
physiology and which was greatly heightened by the fact that at
that time gastric cancer was the most common cause of fatal
human cancers [5]. The late 19th century and the early 20th cen-
tury was a time of great interest and research in gastric physiology
and gastric disease [4,6]. That period was also the time many of the
great gastrointestinal physiologists were making their discoveries.
By 1900, gastric surgery had also begun to emerge as a new field
especially devoted to peptic ulcer disease which was then often
considered a surgical disease [4]. Duodenal ulcer, previously
thought to be rare was found to actually be very common [4]. It
was recognized that ulcers were somehow related to acid and that
duodenal ulcers were associated with high acidity and gastric can-
cers with absence of acid.Gastric urease
How the stomach protected itself from injury by the highly con-
centrated acid contained within was unclear and the object of con-
siderable research [7,8]. For example, it was known that placing
the leg of a live frog into the stomach through a hole in the abdom-
inal wall would result in digestion of its flesh discounting the pro-
tective effect of a living principle [8]. Urea hydrolysis produced
alkaline ammonia was thought to be a good candidate for the
mechanism of protecting the gastric mucosa from the corrosive
acid resent in the stomach [1]. FitzGerald and Murphy provided
proof of principle that urea could play an important role in protect-
ing the stomach by showing that it was possible to neutralize gas-
tric secretion and heal a duodenal ulcer by giving urea orally and
parenterally to humans [9].
Much of the credit for our current understanding gastric urease
comes from decades of experiments by Kornberg et al. who studied
gastric urease primarily in cats [3,10]. Their comprehensive studies
have served as the basis for modern investigations. The breadth of
Kornberg’s observations included studies on: (a) the effect of acid
secretion on urea breakdown, (b) the effect of the presence of acid
in the stomach, variations in gastric blood flow, and the secretion
of non-acid juice on urea hydrolysis, (c) urea hydrolysis associated
with the passage of urea solution from the gastric lumen to the
blood, (d) the effect of anti-bacterial substances on urea hydrolysis,
(e) the deposition of urease in the stomach, (f) urea and ammonia
content of gastric juice, (g) quantitative aspects of gastric urease
activity, and (h) disappearance of urea from the gastric juice. Their
conclusions, regarding the physiology of urea in the stomach,
included: (a) hydrolysis of urea was associated with its passage
from blood in both parietal and non-parietal secretions to the
lumen of the stomach, (b) the amount of urea hydrolyzed paral-
leled the rate of secretion of acid juice, (c) when urea was added
to the stomach, the rate of urea hydrolysis was determined by
the rate of passage of urea-containing fluid through the mucosa;
the majority of the urea was hydrolyzed in the mucosa before
entering the blood, and finally and most importantly, (d) gastric
urease was microbiological in origin and was closely associated
with the epithelium [1,3,10]. The evidence suggesting a microbial
origin of urease initially rested on the effects of treatment with
antimicrobials, for example, cats with gastric urease activity had
a mean gastric juice urea and ammonium concentration of 0.6
mM and 4.2 mM respectively. Following antimicrobial therapy,
the mean concentrations of urea rose and that of ammonium fell
(3 mM and <0.05 mM, respectively) [3,10].Overall, interest in gastric urease waned after it was shown that
urease was not a mammalian enzyme but rather was likely of
microbial origin [1,3]. Interest was rekindled by the discovery of
H. pylori in 1982 and its role in gastritis and peptic ulcer disease
[11]. After the discovery of H. pylori interest in the role of urease
in human disease was rekindled including the role of gastric urease
in relation to the production of ammonia which had a role in the
neurologic complications of liver disease ranging from hepatic
encephalopathy to hepatic coma [12–18].
The mid-20th century was an era characterized by great inter-
est in peptic ulcer disease. For example, during the 1970s there
were more than 140,000 ulcer operations/year in the United States
[4] and Congress established specific research centers to solve the
ulcer problem known as Centers of Ulcer Research and Education
(CURE) [19]. It was known that duodenal ulcer was associated with
specific abnormalities in the control of gastric secretion and this
guided CURE’s research. The hypothesis of a microbial cause of
peptic ulcer had gone in and out of favor for decades. In the mid-
1970s a group in the UK noted the presence of spiral bacteria asso-
ciated with gastritis and peptic ulcers [20–22]. Attempts to culture
that organism failed. Later, Robin Warren from Australia prompted
by his observations using silver stained gastric sections, also noted
the association of spiral bacteria and gastric inflammation. He was
able to convince a clinical research fellow, Berry Marshall, to join
him and together they were able to confirm their observations
and with the advice of a microbiologist, Adrian Lee, who had spe-
cial expertise with spiral bacteria, and the laboratory services of
Steward Goodwin were able to culture H. pylori and prove it was
etiologically related to gastritis and peptic ulcer. For this, Warren
and Marshall earned a Nobel Prize in 2005 [23].
H. pylori urease
Although initial microbiological studies pointed away from H.
pylori being urease positive, subsequent studies by McNulty et al.
reported copious urease activity [24–26]. McNulty et al. also pro-
duced a clinical test for gastric biopsy urease activity to use a sim-
ple test to diagnose the presence of the organism [24,26]. Marshall
subsequently added an antimicrobial agent to a common labora-
tory urease test and produced the first patented test to detect H.
pylori clinically, the CLO test for Campylobacter-like organisms as
H. pylori was then called. H. pylori urease also proved to be highly
antigenic and is a component of most anti-H. pylori serologic tests
and candidate vaccines.
The tolerance of H. pylori to acid is largely dependent on urease
activity, a cytoplasmic enzyme. Access of urea to the enzyme is
restricted by the presence of a H+-gated pore (UreI) such that in
acidic conditionsurea canenter the cytoplasmic space andbehydro-
lyzed to CO2 and ammonia [27–30]. The gene product is directly
responsible for urea permeability and is active at acidic pH or it reg-
ulates the urea permeability of another cytoplasmicmembrane pro-
tein. The ammonia produced diffuses into the low pH stomach
where it becomes ionized and trapped in the gastric lumenwhereas
the CO2 appears in the blood and subsequently is exhaled.
During the Kornberg era 14C and 13C isotope-based methodol-
ogy was used to identify urease activity non-invasively as quasi-
breath tests in experimental animals including the frog [1,3].
Methods using stable and radioactive isotopes were subsequently
used to develop diagnostic tests in humans utilizing isotopic
enrichment of breath, blood, or urine following oral administration
of labeled compounds, most often urea, to detect the presence of H.
pylori infections [31–37]. Although urea and ammonia can easily
be measured in gastric juice [38], the first clinically useful rapid
tests for diagnosis of H. pylori using gastric contents or biopsies tar-
geted urease and were adaptations of standard laboratory tests for
urease activity and named Rapid Urease Tests (RUTs).
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The fact that H. pylori is both abundant in the stomach and con-
tains urease has been widely used to assist in clinical diagnosis. As
noted above, with a short time after the discovery of H. pylori, rapid
urease tests had been developed to allow rapid detection of H.
pylori using gastric specimens (mucus, biopsy, or brushings).
Although investigators have exploited essentially every method
possible to detect urease activity, methods to detect changes in
pH either directly or using color changes following incubation of
gastric specimens proved both simple and reliable and were most
widely adapted. More sophisticated methods requiring complex
devices to accurately measure pH changes have generally not been
successful clinically because methods based on change in color of a
pH indicator included with the urea substrate are much more con-
venient and both generally cheap and accurate. Most tests use
urea-impregnated agar, liquid, or a dry membrane upon or within
which the sample is placed. The fact that H. pylori urease has a pH
optimum lower (e.g., 5.4) than most other bacteria likely to be
encountered in the stomach led to development of potentially
more specific tests such as the hp-fast which used two different
pH indicators one at a lower and the other at a higher pH
(Fig. 1). Choice of RUT test depends on availability, cost, and ease
of use. In regions where cost is a significant issue, tests are often
made locally from a solution containing 2 g of urea in 100 mL of
0.01 M sodium phosphate buffer, pH 6.5, into which 10 mL of a
0.5% (w/v) phenol red and 20 mg of sodium azide are added.
Approximately 0.5 mL of this mixture is then placed into dram
vials which are then kept in the endoscopy room. The solution is
originally yellow and will turn pink or red typically within 30
min to 3 h after a H. pylori-containing specimen is immersed.
The RUT involves an enzymatic reaction and important consid-
erations for test design include substrate concentration, enzyme
concentration and activity, time, and temperature. Studies have
done to test most of these parameters. The critical variables include
sample collection, sample size, the time required before the test canFig. 1. Examples of commercial rapid urease tests commonly available in the United State
impregnated agar and a pH indicator system. The upper one of each pair is the controlbe scored as positive or negative. For gel-based tests warming will
reduce the time required and commercial warmers that maintain
the sample at 37 C are available [39]. Some endoscopists place
the sample-containing device in their pocket to warm it and check
it when convenient. A positive RUT requires approximately 105 H.
pylori in the biopsy sample to produce a positive reaction with an
agar-based test [40]. The organisms tend to localize on or near
the surface of the specimen such that most of the tissue is ‘‘extra”
and does not contribute to the reaction. Some investigators have
used opened forceps to scrape gastric mucus to ensure that a high
concentration of bacteria-rich material is obtained [41].
Generally, the concentration of H. pylori is highest in the
antrum, however, if the patient has recently taken proton pump
inhibitors (PPIs) the concentration can be markedly reduced result-
ing in a false negative test [42]. Another common cause of false
negative tests, especially in areas where atrophic gastritis is com-
mon, is the presence of intestinal metaplasia which is often devoid
of H. pylori. We recommend that at least two large-cup biopsies be
taken from normal appearing mucosa, one from the antrum and
one from the corpus, avoiding obvious areas of intestinal metapla-
sia. The two biopsies are then combined within the same test well
[40,43]. Many take samples for RUT or culture before taking sam-
ples for histology with the thought that formalin may interfere
with the results of culture or RUT. This caution is unfounded and
there is no reason to request a new forcep if the forceps has been
previously immersed in formalin [43–47]. The RUT is examined
as convenient over 24 h. After 24 h the device should be discarded
as color changes after this time are not a reliable indicator of H.
pylori infection and can usually be attributed to a low level of con-
taminating mouth bacteria finally beginning to be detected.
The sensitivity of various RUT tests as primary diagnostic tests
is high and has been reported to vary between approximately
80% and 100% with a specificity between 97% and 99% [40,48].
The sample imbedded in the gel can also subsequently be used
for additional testing. For example, the sample can be used for
molecular testing for antimicrobial susceptibility [49,50].s. The CLOtest and a second generation test, the hpfast test are shown. Both use urea
and the lower shows the color change indicating probable H. pylori infection.
Fig. 2. This illustrate the details of the urea breath test using 13C-urea which when
ingested is hydrolyzed into 13CO2 and ammonia. The labeled CO2 then is captured in
a bag for subsequent analysis of the relative enrichment of 13CO2:12CO2.
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because H. pylori infection has become increasingly less frequent,
there is often no reimbursement, and many of the patients are cur-
rently taking or have recently received PPIs resulting in false nega-
tive tests. Those with gastric ulcer or a mucosal abnormality would
normally also receive biopsies of the ulcer margin and base along
with other specimens to examine for H. pylori. Whether only taking
samples for RUT is sufficient is not settled but in most instances
additional biopsies are indicated. While, a positive RUT test in the
presence of a high pretest probability (e.g., duodenal ulcer) would
be sufficient to confirm the diagnosis of H. pylori-related duodenal
ulcer, the test results are generally not available during the endo-
scopy procedure and because the patient with a duodenal ulcer
may have a false negative test (e.g., due to PPI or antibiotic use),
most would take additional biopsies for histology. In the US, it
was suggested that the endoscopists hold the samples for histology
until the results of the RUT test were available. If the RUT were pos-
itive, the biopsies could be discarded thus saving the patient many
hundreds of dollars. It is unclear how often this was actually done.
Nonetheless, a negative RUT result is not a reliable indicator of noH.
pylori infection as many factors can influence the result. The role of
RUT testing will therefore depend on the clinical situation and the
pretest probability (i.e., the prevalence of H. pylori locally). Culture
for antimicrobial susceptibility testing is still generally difficult to
obtain and expensive. We suspect that molecular testing will soon
become widely available and the combination of RUT followed by
molecular testing of positive specimenswill likely become themost
common indication for RUT testing.
Studies of liquid-based RUTs and dry filter-paper test have sug-
gested that some new platforms have shorter times to inter-
pretability than agar tests such as the CLO test [51]. Some RUTs
marketed in Europe have reported accurate results within minutes
[52,53]. However, clinical experience has not shown rapid or ultra-
rapid results to be advantageous clinically especially when one
considered the overall problem which includes diagnosis, treat-
ment, follow-up, and associated issues (e.g., gastric cancer risk).Urea breath test (UBT)
As noted previously, the end products of urease hydrolysis of
urea, ammonia and CO2 can be detected non-invasively and thus
form the basis for the innumerable tests that have been developed
for the clinical diagnosis of H. pylori infection. The most commonly
used are breath tests that employ labeled carbon either the stable
isotope 13C or the radioactive 14C (Fig. 2) [31,33]. The labeled urea
is ingested and the enrichment of blood or breath with the isotope
is assessed using a specific detector. The radioactive 14C is usually
detected by scintillation, in contrast the stable isotope 13C mea-
sured by isotope ratio mass spectrometry [54]. Hundreds of varia-
tions of the UBT have been described in which the dose, timing,
formulation of the substrate, use of adjuvants, test meals, type of
detector from different manufactures, etc. have been varied
[55,56]. All have been shown to be effective.
The clinical problem is the possibility of false positive or false
negative tests. False positive tests are most often caused by urea
hydrolysis by mouth bacteria or by urease-containing bacteria in
the stomach [57]. This is particularly likely to occur in the presence
of achlorhydria or hypochlorhydria. Another potential problem is
substrate exhaustion because of the small quantity of 14C-urea
administered or emptying of the labeled substrate before it can
react with the bacterial urease [58]. The ideal test would use a for-
mulation that was immediately available for hydrolysis, remained
in the stomach during the test period, was distributed throughout
stomach, and was exposed to most of the gastric surface. Almost
every imaginable variation has been tired such as having thepatient recline and roll during the test, prior mouth cleansing,
and prior administration of meals to retard gastric emptying
[55,56]. The 14C-urea containing tests typically contain no non-
radioactive (i.e., ‘‘cold”) urea and the tiny amount of substrate
can be rapidly exhausted by hydrolysis by mouth, swallowed, or
non-H. pylori urease-containing organisms in the stomach produc-
ing false positive tests [58]. Radioactive carbon has the advantages
of being cheap and as there is no natural 14CO2 the analysis is sim-
ple. The disadvantage is that many patients wish to avoid exposure
to radioactive material despite the very low doses being adminis-
tered. The test should not be used in children or pregnant women.
Despite these concerns, it has proven to be clinically useful.
13C-urea is relatively expensive and requires special machines
to detect the enrichment of 13CO2 in the breath. Currently, there
are a number of companies that produce gas isotope ratio spec-
trometers that are portable and accurate which has greatly simpli-
fied testing. 13C-urea has been formulated as a powder to be
dissolved in water prior to use, in capsules and in tablets. The
dosage of urea has ranged widely. Because of the expense, the opti-
mum dose is a tradeoff between cost and adequacy. Most of the
tests use between 50 and 100 mg of 13C-urea. Tablets and capsules
have been used to try and reduce contact with oral urease-
containing organisms; however, solid dose formulation also intro-
duce the problems of emptying before dissolving, dissolving
slowly, or not being well distributed within the stomach. That said,
each formulation appears about equal clinically in most countries
especially if citric acid is included. Testing is typically done at least
one hour after the last solid food ingestion. However, small studies
have not shown that food significantly interferes and similar
results were obtained fasting and after a hamburger and fries
and fasting is not an absolute requirement [31,59]. The duration
of the test is important and times from 10 min to 30 min after
ingestion have proved successful. The initial delay is designed to
allow any effects of oral bacteria to dissipate and to obtain a value
near the peak of isotope enrichment. Most of the tests use times of
15–30 min which is generally near the plateau levels. The results
are expressed as delta over baseline (DOB). A baseline breath sam-
ple is collected and the isotope enrichment is compared some
specified time after ingestion of the labeled substrate. The cut-off
is typically a DOB between 2‰ and 5‰ with 2.4‰ and 2.5‰ being
used most often. In most series only about 5% of samples are near
the cut-off. However, this proportion can be much greater espe-
cially in regions where achlorhydria and hypochlorhydria are com-
mon (see below).
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The presence of UreI can be exploited to increase the accuracy
of the UBT especially in stomachs were acid secretion is low, sup-
pressed, or the bacterial load is low. In normal adults the fasting
gastric pH is approximately 1.8. This may increase to 3 or more
in H. pylori infected individuals by the ammonium produced by
H. pylori urease. The intragastric pH will thus be the result of the
intrinsic rate of basal acid secretion and the bacterial load. When
urea is ingested in a stomach with a relatively high pH the acid
gated pore, UreI, may restrict its access to H. pylori urease and
result in low measure urease activity [27–30]. When urea is
administered with citric or malic acid the access of urea to H. pylori
urease is enhanced and the measured urease activity increases. At
the same time, the low gastric pH inhibits non-H. pylori bacterial
ureases from hydrolyzing the labeled substrate and causing false
positive results. Overall, the addition of citric or malic acid in the
presence of H. pylori results in an increase in urease activity (i.e.,
a higher signal) and a reduction in urease activity in those without
H. pylori infections (a lower baseline) thus improving the sensitiv-
ity and specificity of the test [60]. This is especially important in
populations where atrophic gastritis is present and in those taking
acid suppressing medicines such as H2-receptor antagonists. In
those populations the proportion of false positive or false negative
tests is often clinically important [48,56,58,61–65]. There is little
justification for not using citric or malic acid as adjuvants to the
urea breath test. The problem of false positive tests has proven
clinically important in Spain and Korea with tablet formulations
without citric acid [59] and is likely important in other similar pop-
ulations although this has not been examined systematically.UBT in children
The diagnostic accuracy of the standard adult UBT is reduced in
young children [66–69]. The problem is with the scoring of the
urea breath test which is based on the ratio of 13CO2 to 12CO2 in
the breath associated with the influence of age, gender, and basal
metabolic rate to CO2 production. In small children, the relatively
low CO2 production will result in a DOB that is proportionally
higher for a given amount of labeled urea hydrolyzed producing
false positive test results [69]. One common attempt to overcome
this problem has been to arbitrarily increase the UBT cut-off value
[69,70]. This method is arbitrary and a better alternative to assess
the outcome based on the urea hydrolysis rate (UHR) in which
anthropometric variables are used to determine the rate of CO2
production in children. The 13C-urea hydrolysis rate can be esti-
mated from the algorithm developed by Klein et al. [69] which is
based upon measurement of isotopic enrichment and determina-
tion of the carbon dioxide rate derived from estimated resting
energy expenditure (joules).
In essence, the urea hydrolysis rate (UHR) is expressed as the
adjusted product of change in the isotopic enrichment of paired
breath samples expressed as DOB times the carbon dioxide produc-
tion rate (CO2-PR):UHR ¼ DOB CO2PR  0:346294
CO2-PR is calculated from the product adjusted VCO2 value
[VCO2  0.6944]. The VCO2 is calculated from the resting energy
expenditure equation [VCO2 = EE/134.25] from which the EE value
is calculated from the adjusted basal metabolic rate [EE = 334.6 
BMR]. This is also available on line (https://puhrca.otsuka-us.com/-
files/Pediatric%20UHR-CA_UG%20v2.0.pdf). This method is accu-
rate in both children and adults with a cut-off of 10 mg/min [68,69].Comparison of RUT, UBT, and other methods
The UBT and RUT both have advantages and disadvantages [71].
The UBT is noninvasive, simple, and accurate and detects active H.
pylori infections making it the preferred test for both initial diagno-
sis and confirmation of cure. The weaknesses are cost and relative
unavailability in developing countries. The advantages of RUT are
its wide availability and low cost. The main weakness of the RUT
is the requirement for obtaining gastric specimens (i.e., invasive-
ness). It is especially useful when endoscopy is being done for
another indication. Positive tests provide reliable evidence of infec-
tion whereas negative tests cannot be relied on to determine
absence of infection. Both should be available.
H. pylori infections can also be identified by histology of gastric
biopsies. The characteristic histologic finding is the presence of
acute and chronic inflammation called acute-on-chronic inflam-
mation. In addition, the bacteria can often be seen on standard
hematoxylin and eosin staining, however, confirmation by Giemsa,
a silver stain or immunohistochemical staining is more accurate
[72]. Biopsy specimens can also be used for polymerase chain
based molecular testing or for culture. Because everything in the
stomach must eventually appear in the stool, stool antigen tests
have been devised and tests using monoclonal H. pylori antibodies
have proved similar in sensitivity and specificity to the urea breath
test [71]. Finally, antibodies to H. pylori appear in the blood and a
variety of tests mostly testing for specific IgG anti-H. pylori anti-
bodies are widely available. Since the antibody titer often remains
elevated serologic testing is best used for epidemiologic studies
rather than for the detection of active infection or for test of cure.
The choice of the best test is influenced by local H. pylori preva-
lence, availability, cost and clinical setting [72].
Conclusions and future perspectives
What was a medical curiosity, gastric urease, evolved into the
mechanism in an important human pathogen, H. pylori, was able
to thrive in the acidic environment of the stomach which until
recently had been thought to be sterile. H. pylori urease is now used
as a biomarker for the infection and a variety of techniques have
been developed to reliably detect its presence and thus diagnose
the infection. Attempts to find urease inhibitors to use to cripple
the organism and aid in treatment are ongoing. Countrywide H.
pylori eradication programs are being developed as a strategy to
eliminate gastric cancer. Urease inhibitors and/or vaccines which
include urease antigens are likely to play an important role in these
endeavors.
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